SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2024 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of February 1, 2024 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Joseph Monahan (“Executive”).
January 31, 2024 VIA EMAIL Neal Walker Dear Neal:Interim Ceo Agreement • February 27th, 2024 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
This agreement contains the terms of your position as Interim Chief Executive Officer and President (the “Interim CEO”) of Aclaris Therapeutics, Inc. (the “Company”) with an effective date of January 17, 2024.
SEPARATION AGREEMENT, WAIVER AND RELEASESeparation Agreement • February 27th, 2024 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
THE SEPARATION AGREEMENT, WAIVER AND RELEASE (“Agreement”) is made and entered into as of 2/4/2024, by and among Douglas Manion, whose address is , and their heirs, legatees, personal representatives, successors and assigns (“Employee”), and Aclaris Therapeutics, Inc. (“Aclaris” or “Employer”).
